LONDON, Oct 9- Two major SABMiller shareholders came out in support of the brewer's board late on Friday, saying it was right to reject Anheuser-Busch InBev's $100 billion takeover offer. Aberdeen Asset Management, the seventh-largest shareholder with a 1.8 percent stake, said it believes the offer "significantly undervalues" SABMiller.» Read More
Alstom has until June 2 to review General Electric's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.
Alstom is accepting GE's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.
Jeffrey Immelt, General Electric chairman & CEO, discusses how the synergies between GE and Alstrom will likely drive earnings and increase the company's industrial mix.
CNBC's Mary Thompson reports the latest details on General Electric's attempt to acquire French company Alstom.
Nicholas Heymann, William Blair analyst, discusses General Electric's attempt to acquire Alstrom but Germany's Siemens AG is not giving up its pursuit either. Currently GE has the green light from Alstrom shareholders, says Heymann.
CNBC's David Faber reports Siemens will make an offer for Alstonm.
Jared Bernstein, senior fellow at The Center on Budget and Policy Priorities, and Rep. Todd Young, R-Ind., discusses how America's broken corporate tax code can cause companies, like Pfizer, to incorporate outside the U.S.
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.
Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.
The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.
CNBC's Dominic Chu provides a timeline of Bill Ackman's stake in Allergan.
Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.
The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.
CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.